According to filings with the U.S. Securities and Exchange Commission, Affect Therapeutics is raising $18,073,362.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Kristin Muhlner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Affect Therapeutics
Changing the Way the World Treats Stimulant Addiction. Affect is using mobile technology to deliver the worlds first evidence-based, substance-specific recovery program for methamphetamine and cocaine use disorder. We leverage contingency management or monetary incentives to promote abstinence. We are stimulating the brains rewards system in the same way that drugs do to provide positive reinforcement for healthy behaviors. Affect is using mobile technology to revolutionize stimulant addiction recovery. Our data-driven program is personalized, giving members the tools and incentives they need, exactly when and where they need them.

To learn more about Affect Therapeutics, visit http://www.affecttherapeutics.com/

Contact:
Kristin Muhlner, Chief Executive Officer
929-552-2849
https://www.linkedin.com/in/kristinmuhlner/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.